OPEX® Corporation Offers a Simplified, One-Touch Document Scanning Solution with the Introduction of Axis™

 (BUSINESS WIRE)--OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of Axis™, a new document scanner that brings the benefits of one-touch scanning to a simplified, single-bin configuration. Designed for document capture workflows where minimal document preparation, mixed media handling or operational simplicity are priorities, Axis bridges the gap between OPEX’s desktop scanner series and its multi-bin production scanner portfolio.

“We developed Axis in direct response to market demands,” said Dann Worrell, President, Document and Mail Automation, OPEX. “Our customers want to simplify their scanning processes, reduce operating costs, and improve quality. Axis delivers on these priorities by combining our minimal-prep, One-Touch scanning technology with a single-bin design. With a lower market accessible entry point, Axis helps customers process documents more efficiently while achieving more consistent results.”

OPEX’s newest solution is built on a production-class transport architecture, supporting both continuous batch scanning and scan-from-folder workflows on a single platform. It manages auto feed and drop feed, and handles mixed sizes, weights and conditions. Capable of scanning up to 120 ppm, Axis is designed for any scanning operation that handles mixed document types and spends more significant hours prepping documents before scanning. It is ideal for businesses looking for simplified deployment, flexible workstation options, and a focused, purpose-built alternative to multi-bin production systems.

Axis is available in two models to support varying deployment requirements. The Axis includes an integrated workstation with system component mounts, while the AXIS-M (mobile) offers a foldable support structure designed for relocation between work areas or sites.

“Our team is always focused on building new solutions that enable all types of businesses to improve workflow, drive efficiencies, and solve challenges,” said Scott Maurer, President, International Division, OPEX. “Axis represents the midpoint in our document scanning portfolio, providing a cost-effective approach for advanced document capture applications when physical sorting and dedicated, MICR-based payment processing aren’t required.”

The Axis document scanner enables operators to capture documents with a streamlined, one-touch process, reducing manual handling and improving productivity. Axis supports scan-on-demand, overflow, and distributed capture operations, without requiring workflow-specific scanner configurations. With its single output design, Axis is well suited for archive, backfile conversion, and folder-based scanning applications, where documents are captured and returned in their original order. Additional features include an integrated 22” touchscreen display, a rescan feeder, a document conditioning roller, ultrasonic sensors to detect multi-feed conditions, and more.

Axis joins the existing portfolio of advanced document scanning solutions at OPEX, which includes Falcon®+, Falcon®+ RED™, Gemini®, and Velo™ Powered by Inotec®. It is the first OPEX-designed hardware platform to support a customer-supplied PC Controller and planned TWAIN connectivity, expanding deployment flexibility and integration options while maintaining compatibility with OPEX workflows.

OPEX will debut Axis at ARMA InfoCon 2026, scheduled from October 25 through 28, at the Savannah Convention Center in Georgia, with live demonstrations in Booth #803. Axis will also be available for demonstration at our world headquarters in Moorestown, NJ, and EMEA headquarters in Duisburg, Germany.

About OPEX

OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has over 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future. For more information, visit opex.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006807452/en/

Permalink

https://www.aetoswire.com/en/news/54616480

Contacts

For Additional Information

Laura Evans

levans@opex.com

+1.856.727.1100 x 5012

 

illumynt Launches Talorem®, Bringing Engineering Rigor to Smarter Technology Reuse

 COLUMBUS, Ohio -

Proprietary technology platform delivers faster receiving, better asset intelligence, more accurate grading and higher recovery value.

(BUSINESS WIRE) -- illumynt, a technology-driven lifecycle management company serving AI infrastructure, hyperscale, OEM and enterprise environments, today announced the launch of Talorem®, its proprietary technology platform designed to bring greater precision, intelligence and recovery value to the management of advanced computing assets.

Talorem is illumynt’s proprietary technology platform for engineering-grade testing, refurbishment, recovery, grading and asset intelligence at scale. As the technology foundation behind illumynt’s advanced computing lifecycle operations, Talorem brings together OEM-grade testing and qualification, clean room component recovery, centralized grading infrastructure and analytics to create greater intelligence at every stage of the asset lifecycle-enabling faster processing, more accurate grading and higher recovery value.

“Talorem represents how we believe technology lifecycle management needs to evolve,” said Jörg Herbarth, CEO of illumynt. “The more precisely we can identify, test and understand an asset, the better decisions we can make about its next use—and the more value we can recover for our customers.”

The Engineering Rigor Behind Smart Reuse

As infrastructure becomes more complex and refresh cycles accelerate, traditional approaches to IT asset disposition can be limited by manual processes, generalized testing and incomplete asset data. Talorem applies engineering-grade methodology and standardized processes to determine whether technology should be redeployed, repaired, remarketed, harvested for high-value components or responsibly recycled.

Just as importantly, Talorem creates structured asset data throughout the process. As more equipment is processed, that intelligence builds over time, creating more accurate benchmarks, supporting more defensible recovery pricing and enabling lifecycle decisions grounded in observed asset performance rather than assumptions.

Built for the Economics of Advanced Computing

For hyperscalers, OEMs and enterprises, the economics of technology disposition are changing. Hardware is becoming more specialized, individual components can retain significant value even when a larger system reaches end of life, and accurate testing and grading can materially affect decisions around reuse, resale and recovery.

Talorem is built around that reality, combining engineering discipline with asset intelligence to help organizations understand not simply what an asset is, but what it can still do and what it is still worth.

“Circularity is increasingly an engineering and data challenge, not simply a logistics challenge,” Herbarth added. “Talorem gives us the ability to make smarter reuse and recovery decisions at scale while giving our customers greater visibility into the condition and value of their technology.”

About illumynt

illumynt is a technology-driven lifecycle management company helping organizations maximize the value of complex IT and advanced computing infrastructure. Through engineering-grade diagnostics, repair, component recovery, secure processing and asset intelligence, illumynt helps hyperscalers, OEMs and enterprises extend technology lifecycles, recover greater value and make more informed infrastructure decisions.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006382527/en/

Permalink

https://www.aetoswire.com/en/news/0610202657856

Contacts

Alyson Kaye

Alyson.kaye@illumynt.com

617.407.6381

 

30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation

 ZUG, Switzerland - Tuesday, 06. October 2026 AETOSWire  

Galderma celebrates the 30th anniversary of Restylane, its pioneering range of hyaluronic acid (HA) injectables that established the category as the first to market1

With three decades of innovation across technology, packaging, and treatment areas, Restylane continues to meet growing aesthetic needs, including emerging areas such as medication-driven weight loss, skin quality and menopause1-11

This year’s milestones include the approvals of Restylane Shaype™ in the European Union (EU) for enhancement of the chin region, the new state-of-the-art Restylane syringe in the EU, United States (U.S.), and Canada, and Restylane Volyme™* in the U.S. for temple hollowing, with a dual-layer patent-pending technique leveraging both needle and cannula12-18

With more than 80 clinical trials, 180 publications, around 407,000 patients evaluated for safety, and 77 million treatments administered worldwide, Restylane remains a pioneer in science-backed aesthetic innovation and continues to shape the future of HA injectables1-3,19,20

 

(BUSINESS WIRE) -- Galderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30 years since Restylane was launched in Europe as the first hyaluronic acid (HA) injectable.1 With HA closest to the skin’s own, Restylane is designed to deliver personalized, natural-looking outcomes that meet diverse patient needs across key areas of the face, décolletage, and hands.8,10,12,21-31 With three decades of innovation across technology, packaging, and treatment areas, Restylane remains at the forefront of innovation, evolving from its original NASHA®, technology into a comprehensive portfolio spanning three distinct technologies: NASHA HD™, NASHA®, and OBT™.1,8,21,22 Together, these technologies offer solutions ranging from firmer gels that provide contouring and structural support, to soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look.8,12,21-31

The Restylane portfolio has most recently achieved EU Medical Device Regulation certification for the products created with NASHA HD™, NASHA®, and OBT™ technologies.12,23-29 As one of the world's most rigorous medical device regulatory frameworks, the certification reinforces confidence in the strong safety profile, quality standards and scientific foundation behind the portfolio.32

   

 “Restylane's 30-year journey is a testament to Galderma's enduring commitment to science-led innovation in aesthetics. Supported by extensive clinical experience – including more than 400,000 patients evaluated for safety – and robust real-world data, Restylane has helped define aesthetics, setting a high standard for safety, efficacy and natural-looking results since it launched as the first HA injectable three decades ago. With market penetration still relatively low, significant opportunities remain to expand adoption, and as we look to the future, we will continue to build on this foundation through innovation that reinforces the essential role of HA injectables in the future of aesthetics.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.

GLOBAL HEAD OF R&D

GALDERMA

 

   

Expanding Restylane’s versatility to support tailored aesthetic outcomes

Restylane continues to expand treatment possibilities through new technologies, indications, and devices.

Restylane Shaype was recently approved in the EU for correction and enhancement of the chin region.12 Powered by Galderma’s new NASHA HD™ technology, it is the firmest HA injectable gel available among facial filler market leaders, delivering a unique bone-mimicking effect that enables immediate, natural-looking structural enhancement in the lower face.12,21,33 Restylane Shaype is the first minimally invasive injectable aesthetic option to provide structure in this increasingly important treatment area, which has previously largely relied on surgical implants.21

A new state-of-the-art Restylane syringe was also approved in the EU, U.S. and Canada earlier this year, for use with the NASHA® lidocaine Restylane products in multiple facial indications.13-15 It was designed in collaboration with over 70 aesthetics practitioners to be optimized for ergonomic functionality, ease of aspiration, and ease of operation.34-37 It has compact blister-free packaging that is 100% recyclable and reduces in-clinic waste by up to 30% based on volume reduction.38,39 A survey of over 300 healthcare professionals in Brazil who had personal experience using the Restylane syringes found that 89% preferred the next-generation syringe over the standard syringe.40 The next-generation syringe complements Galderma’s patented SmartClick™ syringe for Restylane Skinboosters™, which monitors each micro-dose, allowing injectors to focus on technique ​and placement for enhanced patient safety, precision and control.31,41

As global demand grows for treatments that address the evolving effects on the skin of aging, menopause, and weight loss, Restylane Volyme received U.S. approval in March for the correction of temple hollowing with a dual-layer patent-pending technique leveraging both needle and cannula.16-18 Temple volume loss can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance, a challenge increasingly seen in people undergoing medication-driven weight loss and experiencing age- and hormone-related changes, including menopause.6,18,42

   

 “Restylane has been a trusted part of my practice for many years, thanks to the constant innovations brought to the portfolio in terms of product, indications and even packaging. Today, I treat an increasingly diverse range of individuals seeking personalized, natural-looking results, so having a versatile portfolio that goes beyond volumizing and can provide lift, contour, definition and skin quality improvements across multiple areas of the face and body is invaluable. Supported by decades of science, Restylane gives me the confidence to tailor treatments to each patient’s unique anatomy, goals and stage of life.”

DR. LUDDI LUIZ OLIVEIRA

PLASTIC SURGEON

BRAZIL 

 

   

Restylane expands access to injectable aesthetics for new patient segments

Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and needs including medication-driven weight loss, menopause and skin quality.

Interim results from an investigator-initiated trial showed that combining Restylane Skinboosters with Sculptra® – the first proven regenerative biostimulator – drove progressive improvements in hydration, skin barrier function, and overall skin quality in menopausal women.4,43-46 These results are reinforced by consensus guidelines concluding that Restylane Skinboosters can complement Sculptra in the décolletage for comprehensive body rejuvenation.47

Additionally, Restylane also has an important role in addressing the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.11 The combination of Restylane Lyft™ or Volyme with Sculptra has been shown to deliver visible improvements in skin quality and significantly enhance patient satisfaction and emotional wellbeing.11

Supported by 30 years of innovation and more than 77 million treatments administered worldwide, Restylane has helped define the HA injectable category and continues to shape the future of aesthetic medicine.1-3 With more than 80 clinical trials, 180 publications and around 407,000 patients evaluated for safety, its legacy is built on extensive scientific evidence and clinical experience.3,19 These milestones demonstrate Galderma’s ongoing commitment to using its unique dermatology expertise and strong portfolio to meet the needs of patients and healthcare professionals today and tomorrow.

*Restylane Volyme is known as Restylane Contour™ in the U.S.

About the Restylane portfolio

Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.2,24,48 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.7,10,49 Powered by NASHA HD™, NASHA®, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.8,21,22,33 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.2,50,51 Approved indications vary by market.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.

Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.

Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis.

Nikolis A, et al. A comprehensive interim analysis of skin hydration, barrier function (TEWL), elasticity, and patient satisfaction across two treatment arms. Interim Data on File. April 2026.

Nikolis A, et al. Evaluating the role of small particle hyaluronic acid fillers using micro-droplet technique in the face, neck and hands: a retrospective chart review. Clin Cosmet Investig Dermatol. 2018;11:467–475. doi: 10.2147/CCID.S175408.

Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-72.

Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.

Belmontesi M, et al. Injectable non-animal stabilized hyaluronic acid as a skin quality booster: An expert panel consensus. J Drugs Dermatol. 2018;17(1):83– 88.

Kim J. Effects of injection depth and volume of stabilized hyaluronic acid in human dermis on skin texture, hydration, and thickness. Arch Aesthet Plast Surg. 2014;20:97-103. doi:10.14730/aaps.2014.20.2.97.

Galderma. Data on file. MA-58650. Degree of modification of HA fillers.

Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results.

Restylane® Shaype EU IFU.

Galderma. Data on file. U.S. FDA Restylane syringe PMA supplement approval letter.

Galderma. Data on file. Health Canada Restylane Medical Device License.

Galderma. Data on file. Dekra Restylane next generation syringe report.

Restylane® Contour™. US IFU.

Galderma. Data on file. MA-63365 Study Report. 2025.

Galderma. Data on file. Restylane Contour temple investigator closeout meeting executive summary. 2025.

Park KE, et al. Response of 21 hyaluronic acid fillers to recombinant human hyaluronidase. Plast Reconstr Surg Glob Open. 2023;11:e5457. doi:10.1097/GOX.0000000000005457.

Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid-and lower face. Aesthetic Surg J. 2006;26(Suppl.):S10–17. doi: 10.1016/j.asj.2005.09.009.

Nikolis A, et al. Effectiveness and safety of a new hyaluronic acid injectable for augmentation and correction of chin retrusion. J Drugs Dermatol. 2024;23(4):255–61. doi: 10.36849/JDD.8145.

Öhrlund Å, et al. Differentiation of NASHA and OBT hyaluronic acid gels according to strength, flexibility, and associated clinical significance. J Drugs Dermatol. 2024;23(1):1332–6. doi: 10.36849/JDD.7648.

Restylane® Lyft™. EU IFU.

Restylane® Classic. EU IFU.

Restylane® Eyelight™. EU IFU.

Restylane® Defyne™. EU IFU.

Restylane® Volyme™. EU IFU.

Restylane® Kysse™. EU IFU.

Restylane® Refyne™. EU IFU.

Restylane® Skinboosters Vital Lidocane™. EU IFU.

Restylane® Skinboosters Vital Light Lidocane™. EU IFU.

European Medicines Agency. Available online. Accessed October 2026.

Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).

Galderma. Data on file. MA-64737.

Galderma. Data on file. MA-56005.

Galderma. Data on file. Design and development of the next generation syringe.

Galderma. Data on file. MA-59168.

Galderma. Data on file. Vimer S.r.l. Declaration of recycling compliance. 2025.

Galderma. Data on file. MA-63907.

Galderma. Data on file. Restylane next generation syringe HCP survey.

Landau M, Fagien S. Science of Hyaluronic Acid Beyond Filling: Fibroblasts and Their Response to the Extracellular Matrix. Plast Reconstr Surg. 2015;136(5S):188S–195S. doi: 10.1097/PRS.0000000000001823.

Qin J. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057.

Galderma. Data on File. MA-60875. A Single Center, Double-Blinded, Split-Body, Randomized Clinical Trial of Injectable Poly-L-Lactic Acid for Volumization and Adipogenesis of the Hip Dell.

Huth S, et al. Molecular Insights into the effects of PLLA-SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.

Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS 2024, February 1-3, 2024, Paris, France.

Sculptra®. EU Instructions for Use. 2025. Available online. Accessed October 2026.

Haddad A, et al. International consensus: Sculptra®/Restylane® Skinboosters™ for non-facial rejuvenation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.

Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.

Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.

Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261005211995/en/

Permalink

https://www.aetoswire.com/en/news/0610202657830

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite

  SAN DIEGO - Tuesday, 06. October 2026 AETOSWire Print 

New ultra-high sensitivity tests enable objective, automation-ready, high-throughput clonality and MRD workflow.

 

(BUSINESS WIRE)--Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing (NGS) solution to identify and track immunoglobulin and T-cell receptor gene rearrangements.

As NGS-based immune receptor MRD analysis moves from academic laboratories into routine use in oncology research centers, the demand for standardized, high-throughput workflows is accelerating. Laboratories are seeking both greater efficiency and ultra-high sensitivity. This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites. LymphoTrack Flex meets these demands, bringing seven molecular targets (IGHV leader, IGH FR1, IGH FR2, IGH FR3, IGK, TRB and TRG), together in one automation-ready workflow with massively parallel multiplexing and a powerful bioinformatics engine to provide objective analyses and tracking of clonal sequences.

“Clonality, somatic hypermutation, and measurable residual disease provide complementary molecular insights across the course of lymphoid malignancies, with growing relevance as treatment approaches evolve beyond fixed-duration therapy toward more dynamic, MRD-informed strategies,” said Brad Patay, Chief Medical Officer of Invivoscribe. “LymphoTrack Flex enables laboratories to characterize clonal populations at baseline and select sequence-specific clonotypes for longitudinal assessments, providing a consistent molecular picture of disease over time to support the evaluation of these evolving treatment approaches.”

The software portfolio provides flexibility across laboratory environments. LymphoTrack Software supports local, desktop-based analysis for labs that want to run testing independently on a single workstation. LymphoTrack Enterprise Software provides a centralized environment for high-throughput analysis, standardized reporting, and integration with laboratory and data infrastructures, enabling labs to scale testing volume without re-architecting laboratory workflow.

“Our vision is to give all laboratories access to optimized MRD assays, controls, and analysis software, with one standardized approach,” said Jeff Miller, CEO of Invivoscribe. “I am incredibly proud of the team behind LymphoTrack Flex. This release is the result of decades of multidisciplinary and international clinical laboratory experience.”

With the complete LymphoTrack Flex suite now available, laboratories can implement a flexible, scalable NGS workflow for clonality assessment, somatic hypermutation analysis, and sequence-based MRD research across a broad range of lymphoid malignancies. Laboratories ready to expand or standardize their NGS clonality and MRD capabilities can learn more at LymphoTrack Flex page or contact inquiry@invivoscribe.com to connect with an Invivoscribe specialist.

About Invivoscribe

Invivoscribe is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For more than thirty years, Invivoscribe has advanced the quality of healthcare worldwide by delivering high-quality, standardized reagents, diagnostic assays, sample preparation systems, and bioinformatics solutions that support precision medicine. The company has a proven track record of partnering with pharmaceutical and biotechnology organizations to support clinical trial testing through its global laboratory network in the United States, Germany, Japan, and China, as well as to develop and commercialize companion diagnostics, leveraging deep expertise in regulatory strategy and laboratory services. By offering both distributable diagnostic kits to over 700 clinical laboratory customers and clinical testing services through its globally located clinical laboratory subsidiaries, LabPMM®, Invivoscribe is an ideal partner across the full diagnostic lifecycle - from development and clinical trials through regulatory submission and commercialization.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006900484/en/

Permalink

https://www.aetoswire.com/en/news/54616964

Contacts

For more information, visit www.invivoscribe.com, or contact inquiry@invivoscribe.com

 

Posiflex Unveils AI-Powered SCO Series Kiosk to Accelerate the Future of Self-Service Retail

 

TAIPEI, Taiwan -

A modular, smarter self-checkout platform engineered for weighing, RFID, and loss-prevention automation across diverse retail environments

(BUSINESS WIRE) -- Posiflex Technology, Inc., a global leader in Point of Sale (POS) systems and Online-to-Offline (O2O) solutions, proudly introduces the SCO Series Self-Service Kiosks, an AI-powered platform designed to redefine self-service retail by offering flexible system configurations that support either precise weighing-scale transactions or RFID-enabled automated checkout.

Built to address the evolving needs of both traditional fresh-goods environments and modern RFID-driven retail concepts, the SCO Series enables retailers to elevate operational accuracy, accelerate checkout processes, and future-proof store deployments through modular architecture, intelligent automation, and adaptable form factors engineered for next-generation retail.

AI-Enabled Self-Checkout Solution for Weighing & RFID Applications

Designed for diverse retail environments, the SCO Series offers two dedicated configurations: a weighing-scale model for fresh and bulk goods and an RFID model for tag-enabled retail.

The weighing solution delivers fast and accurate pricing for fruits, vegetables, and bulk items, featuring a durable stainless-steel platform, seamless POS integration, and real-time weight display to ensure precise, efficient self-checkout.

The RFID configuration enables automatic item identification and multi-item contactless reading without barcode alignment, accelerating checkout while improving operational efficiency for apparel, specialty retail, and unattended store applications.

AI-Powered Loss Prevention for an Optimized Checkout Experience

At the core of the platform, AI-driven object recognition reduces manual input, minimizes mis-scanning, and supports behavior anomaly detection. Optional AI loss-prevention capabilities and a large LED status indicator provide real-time alerts, helping retailers easy monitoring, prevent scanning error, and maintain efficient checkout operations.

Modular and Scalable Design for Flexible Deployment

The SCO Series features a modular design that adapts to diverse retail environments and store layouts. Retailers can configure optional modules such as weighing scales, RFID detection, and payment peripherals, including MSR, NFC/RFID readers, and a dedicated EMV mounting bracket.

Powered by flexible Intel® platform options, the system delivers scalable performance for cost-effective deployment from pilot projects to large-scale rollouts.

Flexible Display Installation for User-Centric Design

The SCO Series features a 15.6-inch true-flat PCAP touch display with an optional 10-inch customer-facing display for enhanced engagement. To suit different store layouts, the main display can be installed on either the left or right side, supporting countertop, kiosk, and full-standing deployments.

Developer Tools & Seamless System Integration

Posiflex provides a comprehensive Software Development Kit (SDK) with developer documentation and integration tools, enabling partners to integrate with existing POS systems, build customized workflows, and support advanced features such as AI object recognition and AI loss prevention. This flexible development framework accelerates deployment while supporting evolving retail needs.

Expanding its self-service portfolio, the Posiflex SCO Series now supports floor-standing and countertop deployments, as well as the Datalogic MAGELLAN™ 9600i Module support. A dedicated weighing scale model is also scheduled for release soon, broadening the solution's suitability for supermarkets, grocery stores, and other retail environments.

The Posiflex SCO Series self-service kiosks empower retailers to modernize customer journeys, strengthen operational control, and deliver frictionless checkout experiences in today's rapidly evolving retail landscape.

Learn more about SCO Series, please visit the product landing page: https://www.posiflex.com/promotion/self-checkout-solutions-SCO-series/

About POSIFLEX Group

Posiflex Group is a global leader in Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Scenario-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as a global top-5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261004628458/en/

Permalink

https://aetoswire.com/en/news/0610202657829

Contacts

Media Contact:

Jessie Hsu, Marketing Director, Global Marketing Division

jessiehsu@posiflex.com

 

New Global Survey Finds Majority of VMware Users Are Choosing Alternative Paths for Cost Control, Roadmap Flexibility and Better Support

LAS VEGAS - Tuesday, 06. October 2026

Rimini Street and DBTA/Unisphere Research survey finds 66% are already using or are considering third-party support

(BUSINESS WIRE) -- Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced findings from the 2026 IT Virtualization Survey – What’s Next for VMware Users, a new global survey of nearly 300 VMware user organizations conducted by Unisphere Research on behalf of Rimini Street.

Cost Cited as the Number One Factor in Seeking Alternative VMware Solutions

Key Findings: 90% of respondents said they are considering alternatives to VMware due to higher licensing costs, while 54% cited the end of perpetual license support as another reason to evaluate other options.

The research shows that cost remains the leading driver of virtualization roadmap decisions, with nearly three-quarters of respondents (73%) citing cost savings as a top priority. At the same time, organizations reported significant barriers to progress, including operational complexity (40%), multi-vendor management challenges (38%), securing the increased attack surface (37%) and team skills requirements (37%).

These findings suggest that while organizations are actively pursuing change, they are also looking for ways to reduce risk and avoid unnecessary disruption.

IT Leaders Choose Multiple and Hybrid Hypervisor Models for Greater Control and More Flexibility

Key Findings: 60% are considering a multiple-hypervisor strategy, reflecting growing interest in more flexible, mixed environments that support both operational and financial goals. In addition, 47% are favoring a hybrid IT virtualization environment consisting of hypervisors and containers for "best of both worlds" workload placement.

The findings also suggest that many organizations are considering a range of options beyond VMware Cloud Foundation (VCF). Nearly half of respondents (48%) said they do not currently plan to move any of their assets to VCF, indicating that many enterprises are taking a more measured approach and prioritizing strategies that align with their business needs, existing investments and operating models.

The trend shows increasing diversification in enterprise virtualization strategies with a longer-term transition toward bespoke, multi-platform IT virtualization environments. As organizations reevaluate their paths to modernization, they are increasingly adopting approaches that combine on-premises infrastructure, private cloud, public cloud and alternative hypervisors to support workload flexibility, operational efficiency and better cost control.

Majority of VMware Customers Consider Third-party Support to Protect and Extend the Life of VMware Investments

Key Findings: 66% of respondents are currently using or considering third-party support. Leading reasons cited include security (60%), installation and implementation support (57%), and service and support concerns (54%).

IT security leaders report being overwhelmed by the “vulnerability treadmill.” In virtualized IT environments, a single compromised virtual machine can expose hundreds of guest machines, increasing the risk of service outages and potential data breaches. This makes the hypervisor a high-value target for ransomware and advanced persistent threats.

As VMware customers reassess their virtualization strategies, many are exploring third-party VMware support to strengthen service coverage, maintain operational continuity and extend the value of existing investments. The findings suggest organizations want greater control over how they secure, support and evolve environments.

Further, 77% of IT virtualization security leaders said they would see value in a security solution that provides real-time threat visibility and proactive protection against vulnerabilities, rather than relying solely on Broadcom’s patching program. Together, these findings point to growing demand for more resilient, security-by-design virtualization strategies.

“The shift for current VMware users is not simply about replacing one vendor with another. It reflects a broader effort by enterprises to reduce dependency on a single provider, maintain continuity for mission-critical systems and modernize at a pace that fits their own business requirements,” cited Joe McKendrick, lead analyst, Unisphere Research. “For many organizations, that means balancing support for existing environments with new investments designed to improve resilience, security and scalability over time.”

“Organizations want more choice, flexibility and control over their virtualization strategies,” said Keith Costello, EVP and chief operating officer, Rimini Street. “Our suite of services for VMware helps clients reduce costs, strengthen security, improve support outcomes and extend the value of their existing VMware investments — without being forced into disruptive timelines or one-size-fits-all vendor roadmaps. These survey findings reinforce the need for practical, vendor-independent strategies that put business priorities back on the client’s terms.”

Access the full report, 2026 IT Virtualization Survey – What’s Next for VMware Users, available for download.

Survey methodology

The survey was conducted by Unisphere Research in partnership with Rimini Street. Unisphere Research is the market research unit of Unisphere Media, a division of Information Today, Inc., publishers of Database Trends and Applications magazine and the 5 Minute Briefing newsletters. It surveyed 269 executives, managers and professionals across VMware user organizations between December 2025 and February 2026 to assess current usage, future plans and perceptions of VMware under Broadcom, as well as interest in alternative solutions. All respondents were current users of VMware solutions at the time the survey was conducted.

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation.

To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for ERP software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; our wind down of support services for Oracle’s PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately predict retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States and international governments and capture new contracts with public sector entities; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on July 30, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006014490/en/

Permalink

https://www.aetoswire.com/en/news/0610202657859

Contacts

Janet Ravin

VP, Corporate Marketing

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com

Cities integrating AI into public services with no common framework for assessing readiness, Oxford Insights finds

 London, United Kingdom - Tuesday, 06. October 2026 AETOSWire Print 

Organisation behind the Government AI Readiness Index proposes a City AI Readiness Index, based on a new study of Abu Dhabi

 

Cities are integrating artificial intelligence into public services and operations with no shared framework for measuring or comparing how prepared they are to do so safely, effectively or accountably.

Existing global indices compare countries on legislation, investment and research output, but the AI efforts happening at city level – the level of government where the technology most directly shapes daily life – are not systematically captured.

To start closing that gap, Oxford Insights researchers studied AI readiness across six cities. They found that all share the same core priorities, from governance and funding to talent and infrastructure, but take distinct routes to AI readiness, shaped both by structural conditions and by deliberate strategic choices.

The findings draw on an in-depth study of Abu Dhabi, where researchers were able to observe city-level AI readiness being actively built rather than planned.

The UAE capital was considered alongside five further international cities: Seoul, London, Montreal, Helsinki and Tallinn.

A report published today sets out the foundation for a proposed City AI Readiness Index, giving city governments a comparable reference point to that which national governments have used since 2017 – and giving citizens and residents a clearer picture of how prepared their city is.

"Cities are where most people deal with government, yet there has been no shared way to judge how ready they are for AI," said Richard Stirling, CEO of Oxford Insights. "Our framework will give city leaders that information, and Abu Dhabi was the right place to test it. It has assembled every layer of the AI stack, from compute and energy through models and capital to government as a large-scale user. Applying the framework to other cities then shows the different routes they are taking and what each one relies on."

City AI Readiness: A Deep Dive into Abu Dhabi and the Global Landscape was produced in collaboration with Mohamed bin Zayed University of Artificial Intelligence and Khalifa University.

It finds no single model of AI readiness and identifies areas requiring continued attention as deployment scales, including compute and energy requirements, talent, governance and resilience.

Researchers used a six-pillar framework for understanding AI readiness and identified four city archetypes that can help leaders assess strengths, gaps and priorities for future development.

They are infrastructure-led "Platform Cities", research-driven "Cognitive Cities", service-focused "Delivery Cities" and "Strategic Cities", where AI sits at the centre of government and economic planning.

Abu Dhabi was identified alongside Seoul as a Strategic City.

In January 2025, it launched a three-year strategy to transform into the world's first AI-native government.

TAMM, its agentic AI-powered public services platform used by 4.7 million, now resolves 96 per cent of enquiries autonomously through AI.

Oxford Insights plans to pilot the index across 15 to 20 cities.

About Oxford Insights

Since 2017, Oxford Insights has produced the Government AI Readiness Index — the first global AI index focused specifically on the role of government. Used by countries around the world as a benchmark, the Index features in multiple national AI strategies and informs policy making at the highest levels. Oxford Insights is a research and advisory firm specialising in government AI readiness and digital transformation.

Notes to editors

Report title: City AI Readiness: A Deep Dive into Abu Dhabi and the Global Landscape

Full report available at: https://oxfordinsights.com/city-ai-readiness-ad/

Publication date: 6 October 2026

Permalink

https://www.aetoswire.com/en/news/0610202657810

Contacts

Katie Haigh

katie.haigh@oxfordinsights.com

Mary Kay Introduces the K-Beauty Texture Edit

 Special-Edition Korea-Made Skin Care Collection Launches In 40 Markets, Available While Supplies Last

 

(BUSINESS WIRE)--Mary Kay Inc., the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, a special-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September.

Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty Texture Edit was designed to resonate with a global cultural beauty movement captivating the next generation. The trend-forward collection includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel.

The launch marks another exciting milestone in Mary Kay's ongoing evolution as the company expands its global reach, connects with a new generation of beauty enthusiasts and continues to support the Independent Beauty Consultants and loyal customers who have powered its success for decades.

Launching just one month after the debut of Beauty Is More Beautiful Shared™, the K-Beauty Texture Edit brings the platform’s philosophy to life through products designed to spark discovery, conversation, and shared beauty experiences. It also reflects Mary Kay’s strategy of blending globally inspired innovation with the personalized service and relationships that remain central to the Mary Kay experience.

“Mary Kay’s legacy has always been rooted in innovation, listening to consumers, and evolving with the culture of beauty around the world,” said Dr. Lucy Gildea, Chief Brand and Scientific Officer of Mary Kay Inc. “The K-Beauty Texture Edit brings that spirit to life by translating global beauty trends into meaningful experiences for consumers and our Independent Beauty Consultants. As part of Beauty Is More Beautiful Shared™, it also helps us build awareness and relevance with the next generation of beauty consumers while honoring the heritage that connects us all.”

The Mary Kay K-Beauty Texture Edit includes three familiar steps – cleansing, patches, and moisturizing – in fun, sensorial formats. Each product fits easily into an existing routine, so customers can try something new without changing what already works. The collection features:

Mary Kay® Melt-In Cleansing Balm – a transformative balm-to-oil-to-milky cleanser featuring regenerative PDRN1 (salmon DNA) infusion, rice bran oil, and vitamin E that helps leave skin feeling soft and clean.

Mary Kay® Snail Gel Face Patches – cooling hydrogel face patches formulated with snail mucin, niacinamide, licorice extract, and multiple forms of hyaluronic acid to help hydrate and brighten the appearance of skin.

Mary Kay® Collagen Moisturizing Gel – a bouncy jelly moisturizer featuring collagen peptides, niacinamide, and squalane to deliver hydration and a plump, glass-skin-inspired glow.

The K-Beauty Texture Edit was created to appeal to next-generation consumers while remaining accessible to existing customers, pairing trend-driven innovation with a distinct Mary Kay approach to beauty and relationships across generations.

Through its global network of Independent Beauty Consultants, Mary Kay continues to create personalized beauty experiences that connect customers with products, education, and community. The K-Beauty Texture Edit extends that opportunity by giving consumers a fresh way to explore one of the world's most influential beauty movements through a trusted global brand.

The Mary Kay K-Beauty Texture Edit will be available beginning October 5, 2026, on Mary Kay’s website and through Mary Kay Independent Beauty Consultants in participating markets worldwide, while supplies last.

Beyond ongoing product innovation, Mary Kay recently announced new ways to invite the next generation of consumers to engage with the brand:

Mary Kay’s My Shop platform: Launched in the U.S. and Germany in 2025, expanded into Canada, Mexico and Spain this summer, “My Shop” is being progressively rolled out globally. My Shop has been designed to meet consumer buying experience needs and speak to a digitally native generation who demand convenience, choice and seamless interactions all in one. The Mary Kay My Shop also provides Independent Beauty Consultants with personalized digital storefronts connected to e-commerce, payments, fulfilment and social media empowering them to serve customers where they are.

In March 2026, Mary Kay launched its “Global Social Squad” bringing together more than 70 Independent Beauty Consultants across 15 markets as social creators.

Beauty Tech: Mary Kay’s AI-powered Foundation Finder analyzes 151 facial points to recommend shades directly from the phone in just seconds. Mary Kay Foundation Finder was recently recognized as a finalist in the 2026 Gartner Eye on Innovation Awards for Retail & Consumer Goods.

Did You Know:

Mary Kay ranked #8 out of 5,500 brands on Forbes’s 2026 Best Brands for Social Impact2 moving up from stellar #9 achieved in 2025. Mary Kay is the only beauty brand in the Top 15 and the only direct selling company on the list.

Mary Kay ranked #2 on Forbes 2026 Best Customer Service list moving up from #93 in 20253. Mary Kay is the only Beauty brand in the Top 15 and the only direct-selling company in the Top 50.

Mary Kay was named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World4 by Euromonitor International for four consecutive years (2023-2026).

ABOUT MARY KAY

For more than 60 years, Mary Kay has empowered generations of women around the world to discover beauty together, build meaningful futures and find a community of women who celebrate one another. Founded by Mary Kay Ash in 1963, the global beauty company has connected women across 40 markets through innovative skincare, color cosmetics, fragrances, and wellness products. Mary Kay transforms purpose into action by advancing causes that support women and families, investing in scientific innovation, and working toward a more sustainable future. At its core, Mary Kay is dedicated to enriching women's lives and creating opportunities for women to thrive together. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn.

____________________________________

1 Polydeoxyribonucleotide (PDRN) is a mix of purified Salmon DNA fragments.

2 Alan Schwarz (March 17, 2026). Forbes - Best Brands For Social Impact 2026. https://www.forbes.com/lists/best-brands-social-impact/

3 Alan Schwarz (October 14, 2025). Forbes - Best Customer Service 2026. https://www.forbes.com/lists/best-customer-service/

4 “Source Euromonitor International Limited; Beauty and Personal Care 2026 Edition, Value Sales at RSP, 2025 Data”

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261005600130/en/

Permalink

https://www.aetoswire.com/en/news/54615169

Contacts

Mary Kay Inc. Corporate Communications

newsroom.marykay.com

972.687.5332 or media@mkcorp.com

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

CHICAGO - Monday, 05. October 2026


    Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas
    Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers
    Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1

 

(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment.

The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics-focused Contract Development and Manufacturing Organization (CDMO) site, this acquisition broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, while driving reliable patient access to novel radiopharmaceuticals. It also further enables GE HealthCare’s ability to provide solutions along every step of the theranostics pathway, from cyclotrons to imaging technology, digital workflow tools and radiotherapeutics infrastructure.

“The PET radiopharmaceutical market is expanding rapidly with the introduction of innovative radiotracers and advances in precision care, including the growing adoption of targeted therapies. As part of GE HealthCare, SOFIE Biosciences is expected to grow in the low double digits, and enables us to participate across the radiopharmaceutical value stream, meeting customer demand through a mix of GE HealthCare owned and partner facilities. SOFIE Biosciences has a highly skilled team with deep expertise serving U.S. customers, including manufacturing our Flyrcado™ (flurpiridaz F18 injection) product,” said Kevin O'Neill, President & CEO of the PDx segment at GE HealthCare. “We will leverage our scale and expertise in radiopharmaceutical manufacturing across the U.S., Europe and Japan to further invest in and grow SOFIE Biosciences, helping improve patient access, strengthen reliability of supply, and support the next generation of precision care products."

PET radiopharmaceuticals are used in precision medicine to visualize metabolic and molecular activity and, increasingly, to deliver targeted therapies across a range of disease areas. F18 labeled PET radiopharmaceuticals have a 110-minute half-life, with PET CMOs playing a crucial role in enabling timely and reliable patient access, both to existing and pipeline products. Industry-wide, the radiopharmaceutical pipeline is growing rapidly, with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development.2 These include SOFIE Biosciences’ Phase III F18 Fibroblast Activation Protein Inhibitor (FAPI) asset, FAPI-74, for which GE HealthCare already holds outside-of-U.S. rights. FAPI has the potential to further expand an already fast-growing global PET imaging market, and is showing strong potential for diagnostic and theranostic use across a range of oncologic and non-oncologic indications.

GE HealthCare will continue to drive and expand access to its existing proprietary F18 radiopharmaceutical products, while advancing its pipeline of new products, both through SOFIE Biosciences, and PDx’s other established CMO partners across the U.S.

Serving SOFIE Biosciences’ Customers

Following the transaction close, SOFIE Biosciences will continue to operate as an independent manufacturing partner to its customers, supplying its existing product portfolio, including products from other leading radiopharmaceutical providers.

Patrick Phelps, SOFIE Biosciences co-founder, President & CEO, said, “As demand continues to increase for F18 products, and pipelines for new diagnostics and therapeutics continue to expand, joining GE HealthCare marks an exciting step in our journey as a leading U.S. CMO. With Trilantic North America’s support, we have significantly expanded our capabilities and scale, and we share GE HealthCare’s ambition to improve patient outcomes by delivering on the promise of radiopharmaceuticals as we look ahead to our next phase of growth.”

Ted Rosenwasser, Partner, Trilantic North America, said, "We are incredibly proud of what Patrick and the SOFIE Biosciences team have accomplished during our partnership. SOFIE Biosciences has grown significantly, investing in its network and manufacturing capabilities to help meet growing demand and enable increased and reliable patient access to critical products. GE HealthCare's legacy and global expertise make it a natural partner to support SOFIE Biosciences’ continued growth and help expand access for U.S. patients to novel diagnostic and therapeutic radiopharmaceuticals.”

GE HealthCare’s Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support 140 million procedures in 2025, equivalent to four patient procedures every second. For more than 40 years, GE HealthCare's imaging agents have been routinely used across care pathways to support diagnosis.

Financial Benefits

GE HealthCare estimates that the transaction will be accretive to revenue growth, Adjusted earnings before interest and taxes margin* and Adjusted earnings per share* in the first full year of ownership.

Advisors

For GE HealthCare, BofA Securities, Consello Financial LLC and Solomon Partners Securities LLC served as financial advisors.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction including the financial performance of the business, industry positioning, and GE HealthCare Technologies Inc.’s (“the Company’s”) business, products, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

About SOFIE Biosciences

SOFIE Biosciences' mission is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With a robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and high-value Theranostic intellectual property, SOFIE Biosciences is delivering on the promise of radiopharmaceuticals. For more information, please visit www.sofie.com or info@sofie.com.

About Trilantic North America

Trilantic Capital Management L.P. ("Trilantic North America") is a growth-focused middle market private equity firm focused on control and significant minority investments in North America. Trilantic North America's primary investment focus is in the business and consumer services sectors. Since inception, Trilantic North America has managed seven private equity fund families, representing $11.6B in raised capital commitments. For more information, visit www.trilanticnorthamerica.com.

*Non-GAAP financial measure; see our earnings release dated July 29, 2026 for definitions.

References:

1. https://researchintelo.com/report/fapi-pet-imaging-market
2. MEDraysintell Report, 2025 Edition

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261005273717/en/

Permalink
https://www.aetoswire.com/en/news/54616110

Contacts

GE HealthCare Media Contact
Emmy Elguizaoui
+1-978-243-7503
emmy.elguizaoui@gehealthcare.com

GE HealthCare Investor Relations Contact
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com

SOFIE Biosciences / Trilantic North America
Prosek Partners
Pro-trilantic@prosek.com

Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt

 In a first-of-its-kind mission, TII’s probe aboard the MBR Explorer will journey past six asteroids in the main belt before landing on 269 Justitia, making it only the seventh asteroid in history to be reached on its surface by a probe

Designed, built and tested in Abu Dhabi, TII’s probe is the mission’s only deployable payload, operating fully autonomously around and on Justitia

Thought to have formed in the distant Kuiper Belt in the outer Solar System, 269 Justitia may preserve clues to how water and organic material were distributed during the formation of the planets

Watch the EMA hero film here

 

The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main belt before culminating in a rendezvous with and landing on the seventh, 269 Justitia. If successful, the landing will make Justitia only the seventh asteroid in history to be reached on the surface by the probe.  

Designed, built and tested end-to-end in Abu Dhabi by TII’s Propulsion and Space Research Center, in collaboration with the UAE Space Agency, as well as HEX20, Khalifa University and UAE University’s National Space Science and Technology Center, the TII-built probe is the mission’s only deployable payload. It will separate from MBR Explorer to make contact with Justitia’s surface at the furthest point of the mission and operate fully autonomously in deep space, capturing close-range images and excavating its surface to provide new insights into its composition and physical characteristics. 269 Justitia is thought to have formed in the Kuiper Belt before migrating into the main asteroid belt during the early formation of the Solar System.

H.E. Faisal Al Bannai, Secretary General, Advanced Technology Research Council, the Abu Dhabi Government entity overseeing TII, and Member of the UAE Supreme Space Council, said: “If you want to build serious technological capability, you take on a problem that forces you to push further. For this mission, that means a probe that must make decisions and operate on its own in deep space. And our teams have built that technology here in the UAE. The mission might still be ahead, but we have already expanded what we know how to build. That is how sovereign capability grows. We solve a difficult problem, then set our sights on a bigger one.”

269 Justitia is among the reddest bodies ever observed in the main asteroid belt. Its spectrum more closely resembles objects in the Kuiper Belt beyond Neptune than neighboring asteroids, suggesting it may have formed in the cold outer Solar System, beyond the distance at which methane and methanol freeze, before migrating inward early in the Solar System’s history to its current orbit in the main asteroid belt.  Its surface is thought to be covered in complex organic material produced by the irradiation of that ice. Reaching such a body without a decade-long voyage to the Kuiper Belt itself gives the international scientific community access to material that is otherwise far beyond practical reach, and to evidence bearing on how water and volatiles were distributed as the planets formed.

Dr. Najwa Aaraj, Chief Executive Officer, TII, said: “EMA Probe demonstrates what becomes possible when advanced research is translated into mission-ready engineering. Our teams at TII have developed a system designed to withstand extreme conditions, operate with exceptional precision, and deliver meaningful science billions of kilometers from Earth. The mission reflects not only the caliber of our talent, but the depth of scientific and engineering capability the UAE has built to contribute to some of the world’s most ambitious space missions.”

The MBR Explorer spacecraft will travel approximately 5 billion kilometers over eight years, using gravity-assist maneuvers at Venus, Earth and Mars, and conducting close encounters with six asteroids before arriving at 269 Justitia. The spacecraft is scheduled to launch from Japan in March 2028 within a narrow three-week launch window aligned to interplanetary conditions. Because the spacecraft itself cannot safely approach within a few kilometers of the surface, the probe will separate, make contact with the surface, and deliver the mission’s closest observations.

Dr. Elias Tsoutsanis, Chief Researcher, Propulsion and Space Research Center, TII, said: “The engineering challenge is not simply reaching Justitia, but ensuring the probe can survive an eight-year journey and still perform precisely when it matters most. Every element – from the hardware and thermal design to the onboard software – has been engineered and tested for that final encounter.”

The probe operates fully autonomously throughout its mission, receiving no command from Earth or the MBR Explorer spacecraft after launch. Its onboard software determines when to image, how many images to capture, and which are worth keeping, a capability that rests on the digital processing unit designed and developed by TII – the board that handles the probe’s processing, image selection and power management. The probe does not wait until reaching Justitia to begin; it images throughout the cruise alongside the spacecraft’s other payloads, transmitting data back at approximately six-month intervals. Two cameras, one wide-field and one narrow-field, cover both context and high-resolution data.  

Dr. Anton Ivanov, Principal Investigator and Executive Director, Propulsion and Space Research Center, TII, said: “What makes this probe distinctive is the level of independence engineered into such a compact system. Once deployed, it must sense, decide and operate on its own, far beyond Earth. The program has also helped train Emirati engineers and strengthen the advanced capabilities needed to build a globally competitive space technology ecosystem in the UAE.”

On arrival, the MBR spacecraft will spend approximately seven months in orbit around Justitia, beginning at 250 kilometers and descending through a series of lower orbits. The probe will deploy during a low-altitude pass in early 2036, then descend and make contact with the surface, imaging continuously and transmitting to the spacecraft above. The subsequent images will then allow scientists to study material beneath the surface layer that cannot be characterized from orbit.

EMA is the UAE’s second interplanetary mission and the first in which the spacecraft element has been designed, engineered, assembled and tested within the country. The mission sits within a broader national commitment to the sector. In May 2026, the Supreme Space Council approved a AED 1 billion International Space Cooperation Program intended to connect UAE research institutions with counterparts internationally, localize advanced space technologies, and develop Emirati talent, in support of the National Space Strategy 2031.

For more information, visit www.tii.ae 

Permalink

https://www.aetoswire.com/en/news/tii02102026e

Contacts

Thushara Mohanan, thushara.mohanan@tii.ae

LTM Launches BlueVerse™ AgenTraceIQ

 MUMBAI, India - Monday, 05. October 2026

Offering stems from Rubrik’s Project Hourglass, an alliance helping organizations scale agentic AI securely

 

(BUSINESS WIRE)--LTM, the Business Creativity partner to the world's largest enterprises, today announced the launch of BlueVerse™ AgenTraceIQ, an offering designed to help organizations securely adopt and scale agentic AI. Combining Rubrik Agent Cloud with LTM's AI governance and managed services expertise, the offering enables organizations to monitor AI agents, establish guardrails, and rewind unintended agent actions across business-critical environments.

As part of Rubrik’s Project Hourglass, LTM and other elite Global Systems Integrators partner with Rubrik, the Security and AI Operations Company, to deliver Rubrik Agent Cloud for Anthropic's Claude Code to their enterprise clients. The collaboration strengthens the ability for organizations to adopt agentic systems with the necessary security, governance, and resilience at scale.

"As AI agents increasingly act autonomously, the stakes for enterprise security and resilience have never been higher. Together with LTM, we are empowering organizations to move from reactive risk management to a proactive, secure framework, ensuring they can innovate with AI at speed without compromising their operational integrity." — Alok Agrawal, Chief Solutions Officer, Rubrik.

As AI agents become increasingly embedded in enterprise operations, organizations need a structured approach to managing risk, accountability, and operational continuity. Scaling beyond experimentation requires greater oversight of agent behaviour, stronger policy enforcement, and the ability to respond quickly when unexpected outcomes occur.

BlueVerse™ AgenTraceIQ addresses these challenges through an integrated framework that combines agent observability, governance, and resilience. Powered by Rubrik Agent Cloud and operationalized through LTM's governance-led services model, the offering brings together enterprise-ready advisory, deployment, and managed services to support responsible AI adoption at scale.

The solution provides continuous visibility into agent activity, enforces policy-driven controls and zero-trust access, and enables rapid restoration of systems, data, configurations, and repositories following unintended or destructive actions. By linking agent actions to prompts, plans, and tool interactions, it enhances explainability, auditability, and root-cause analysis. BlueVerse™ AgenTraceIQ supports leading agent ecosystems, including Microsoft Copilot Studio, Salesforce Agentforce, Amazon Bedrock, Anthropic Claude, and custom-built frameworks.

"Agentic AI is rapidly reshaping enterprise operations, but scaling adoption requires more than deploying intelligent agents. Organizations need the ability to understand agent behaviour, establish accountability, and respond quickly when unexpected outcomes occur. Together with Rubrik, BlueVerse™ AgenTraceIQ helps enterprises move from experimentation to trusted, production-scale AI operations," said Krishnan Iyer, Chief Growth Officer, LTM.

The offering also includes AI Resilience Assessments, Governance Framework Design, Deployment & Integration Services, and Managed Governance Operations, helping organizations establish enterprise-ready operating models for agentic AI. By combining Rubrik's technology with LTM's AI transformation expertise, BlueVerse™ AgenTraceIQ enables organizations to accelerate adoption, strengthen compliance readiness, and improve operational certainty as AI becomes embedded across the business.

To learn more about BlueVerse™ AgenTraceIQ , click here.

About LTM

LTM — a Larsen & Toubro Group Company — is an AI-centric global technology services company and the Business Creativity partner to the world’s largest enterprises. We bring human insights and intelligent systems together to help clients create greater value at the intersection of technology and domain expertise. Our capabilities span integrated operations, transformation and business AI — enabling new ways of working, new productivity paradigms and new roads to value. Together with over 87,000 employees across 40 countries and our global network of partners, LTM owns outcomes for clients, helping them not just outperform the market, but Outcreate it. Read more at LTM.com.

RUBRIK® and the Rubrik logo are registered trademarks of Rubrik, Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260925050912/en/

Permalink

https://www.aetoswire.com/en/news/54610941

Contacts

Media Contact: Gitanjali Sreepal | Global Media Relations | gitanjali.sreepal@ltm.com

JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope

 TOKYO -

(BUSINESS WIRE) -- JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026.

HAXIS Low-angle Ion Milling Scanning Electron Microscope

Background of development

As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods.

JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques.

HAXIS is JEOL's new semiconductor failure analysis platform that combines such technologies.

It has realized clear and highly reproducible PVC observation even with advanced semiconductors. By visually detecting electrical anomalies while minimizing the effects of processing damage and contamination, it is possible to efficiently identify the defect location and determine the cause. The use of argon (Ar), an inert gas, ensures stable surface quality and reduces running costs.

The quality of PVC observation is significantly affected by the surface condition of the sample after delayering. HAXIS uses a unique Low-Angle Ion Milling (LIM) delayering technique using Ar ion beams to create a flat surface with minimal damage to the sample surface. This enables clear and highly reproducible PVC observation while retaining structure and potential information even in advanced devices.

Semiconductor failure analysis involves multiple steps, from defect localization to physical analysis and root-cause investigation. As device complexity increases, shortening the turnaround time from failure detection to actionable results becomes increasingly critical.

HAXIS introduces a new approach to failure localization by integrating LIM delayering with SEM imaging and passive voltage contrast (PVC) analysis. This combined workflow enables rapid and highly accurate identification of failure locations, supporting QTAT (Quick Turnaround Time) failure analysis and accelerating the transition from electrical failure detection to physical analysis and root-cause identification.

Main features

Clear PVC imaging

Cost effective Ar processing

Damageless Delayering with LIM

Layer-by-layer LIM / PVC Analysis

Contamination free transfer

Sales target

15 units / year

Product Overview

HAXIS LIM-SEM Multi Beam System

https://www.jeol.com/products/scientific/sem/haxis.php

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260928207899/en/

Permalink

https://aetoswire.com/en/news/0510202657797

Contacts

JEOL Ltd.

3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan

Izumi Oi, President & CEO

(Stock code: 6951, Tokyo Stock Exchange Prime Market)

https://www.jeol.com/

JEOL Ltd.

SI Sales Division

webmaster@jeol.co.jp

https://www.jeol.com/contacts/products.php

 

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

 LEXINGTON, Mass. - Monday, 05. October 2026 AETOSWire  

Survival estimate remained at 48% between years two and three, extending evidence of durable benefit

Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer

 

(BUSINESS WIRE) -- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada.

Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive and off all therapy.

These results come from a population with substantial prior treatment. Patients had received a median of four prior lines of therapy, and 66% had received at least four. All had previously received platinum chemotherapy, 77% had received bevacizumab and 57% had received a PARP inhibitor. Nearly three-quarters had platinum-resistant or refractory disease, meaning their cancer had progressed during platinum treatment or returned within six months of it.

“In recurrent ovarian cancer, conventional checkpoint immunotherapy has rarely produced lasting benefit, particularly after the disease stops responding to platinum chemotherapy,” said Rebecca L. Porter, MD, of Dana-Farber Cancer Institute, who presented the data. “What stands out with longer follow-up is the survival plateau in patients who had already received multiple treatments. That pattern suggests that a different approach to activating the immune system may offer some patients lasting benefit, even when treatment options have narrowed.”

Three-year follow-up findings

Overall efficacy results (n=35)

Overall survival (OS): Estimated survival was 48% at both two and three years. Median OS was 14.8 months.

Objective response rate (ORR): 23% of patients (8/35) had a response, including one complete response and seven partial responses.

Duration of response: Responses lasted a median of 9.7 months.

Clinical benefit: 31% of patients (11/35) had a response or stable disease lasting at least 24 weeks.

Alive and off treatment: At last follow-up, 25% (11 of all 44 patients who received at least one dose of treatment) were alive and off all therapy.

Results by patient subgroup

Platinum-resistant or refractory disease (n=25): Estimated three-year survival was 47%. ORR was 20% (5/25), including one complete and four partial responses.

Platinum-sensitive disease (n=10): Estimated three-year survival was 45%. Thirty percent (3/10) of patients had a partial response.

Four or more prior lines of therapy (n=23): Estimated three-year survival was 48%. ORR was 17% (4/23), with all four responses being partial responses.

Disease progression on a PARP inhibitor (n=17): In patients whose cancer had progressed during PARP inhibitor treatment or maintenance, estimated three-year survival was 61%. Two patients (12%) had partial responses.

Safety remained consistent with the known BOT+BAL profile. No new safety signals or treatment-related deaths were reported.

“The most compelling finding is that the survival curve extends beyond two years in women who had already received multiple treatments, including those with platinum-resistant or refractory disease,” said Steven J. O’Day, MD, Chief Medical Officer of Agenus. “We have seen a similar pattern of durable survival in other difficult-to-treat cancers studied with BOT+BAL. This three-year ovarian update strengthens our conviction that the combination can deliver meaningful, lasting benefit to a subset of patients who have had few effective immunotherapy options.”

The three-year ovarian results add to a pattern of long-term survival across difficult-to-treat cancers studied with BOT+BAL. In the broader 400+ patient Phase 1b pan-tumor analysis, estimated two-year survival was 39%. In a separate cohort of patients with refractory MSS metastatic colorectal cancer without active liver metastases, estimated survival was 41% at two years and 33% at three years. These findings are particularly notable in cancers where conventional immunotherapy has historically offered limited benefit.

The consistent and durable BOT+BAL activity in heavily pretreated cancers that are poorly immunogenic or resistant to prior immunotherapy, reinforced by deep pathologic responses in neoadjuvant studies, strengthens the rationale for moving treatment earlier in the course of disease. Before surgery, when the primary tumor and surrounding lymph nodes remain intact, BOT+BAL may have the greatest opportunity to generate lasting antitumor immunity, reduce recurrence and ultimately increase the number of patients who may be cured.

The full presentation can be found on the publications section of the Agenus website at www.agenusbio.com/publications.

BOT and BAL are in development and have not been approved by the U.S. Food and Drug Administration.

Presentation details

Abstract Title: Next Generation Immune Checkpoint Inhibition with Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer: Results by Platinum Sensitivity Status and 3-Year Overall Survival

Presenter: Rebecca L. Porter, MD; Dana-Farber Cancer Institute, Boston, MA, USA

Poster Presentation number: 969

Session Title: Poster Rounds with Professors Session, Ovarian Cancer 03 Session

Date/Time: Saturday, October 3, 2026 | 10:50am-10:55am EDT

About the C-800-01 Study

C-800-01 (NCT03860272) is a multicenter Phase 1b trial evaluating BOT with or without BAL in advanced solid tumors. The ovarian cancer cohort included patients with recurrent disease for whom no standard therapy was available or whose cancer had progressed after standard treatment. The efficacy analysis included 35 patients who had at least one tumor scan after starting therapy. The safety population included all 44 patients who received treatment. The data cutoff for this analysis was December 13, 2025.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Agenus’ Commitment to Patient Access

Until marketing authorization is granted, BOT+BAL is accessible only through clinical trials and authorized early access mechanisms where permitted and available under each country’s regulatory framework. For eligible French patients treated in hospitals under AAC and meeting the predefined criteria, BOT+BAL is fully reimbursed by France’s national health system. Outside France, access may be available in select countries through paid named-patient programs, which may involve out-of-pocket costs to the patient or coverage under applicable national or private reimbursement arrangements. These programs are physician-driven and are not promotional.

About Botensilimab (BOT)

Botensilimab (BOT) is a human multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. BOT augments immune responses across a wide range of tumor types by priming and activating T cells, reducing intratumoral regulatory T cells, activating myeloid cells and inducing durable memory responses.

Approximately 1,500 patients have been treated with BOT and balstilimab (BAL) in phase 1 and phase 2 clinical trials. The combination with Agenus’ investigational PD-1 antibody, BAL, has shown clinical responses across more than nine cancers. For more information about BOT trials, visit www.clinicaltrials.gov.

About Balstilimab (BAL)

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261003256338/en/

Permalink

https://www.aetoswire.com/en/news/0510202657782

Contacts

Investors

917-362-1370 | investor@agenusbio.com

Media

781-674-4422 | communications@agenusbio.com